Study designed to evaluate the safety and efficacy of double staining with brilliant blue G 0.025% as an adjuvant to macular surgery. Patients undergoing surgery for macular hole or epiretinal membrane will be included. Safety will be evaluated by optic coherence tomography, pattern reversal electroretinogram and multifocal electroretinogram.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
22
Double staining with brilliant blue G 0.025% for macular surgery
Asociación para Evitar la Ceguera en México
Mexico City, Mexico City, Mexico
Thickness of ganglion cell layer - inner plexiform layer measured by optical coherence tomography
Average thickness of ganglion cell layer - inner plexiform layer measured by spectral domain optical coherence tomography
Time frame: 6 months
Amplitude of pattern reversal electroretinogram
Amplitude of pattern reversal electroretinogram (in microvolts)
Time frame: 6 months
Amplitude of b-wave of multifocal electroretinogram
Measurement of the amplitude of the b-wave of multifocal electroretinogram
Time frame: 6 months
Visual acuity
Visual acuity measured with an Early Treatment Diabetic Retinopathy Study chart
Time frame: 6 months
Complications
Presence of any ocular complication
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.